Anticancer Therapies – Products

MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen progression and radiographic progression.

LungExpress Dx™ is a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage NSCLC.

L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic, non-small cell lung cancer.

U.S. patent and trademark office has issued an official notice of allowance for a new U.S. patent specific to the DPX-0907 therapeutic cancer vaccine.

Publication of a research article by OSU investigators demonstrate that LOR-2040, improves the anticancer effects of the chemotherapy drug Ara-C.

Publication of a research article by OSU investigators demonstrate that LOR-2040, improves the anticancer effects of the chemotherapy drug Ara-C.

This new catalog of unusual amino acids for peptide synthesis includes over 350 high purity amino acid analogs, substituted amino acids, beta-homo amino acids, pseudoproline dipeptides, products for stapled peptides, glyco-amino acids, peptide nucleic acid (PNA) monomers and amino-PEG acids that can be incorporated into peptide products to enhance their pharmaceutical characteristics.

Test aims to identify FLT3 positive AML patients for specific use in connection with the Novartis development compound, midostaurin (PKC412).

Collaboration and licensing partners fund efforts in local and systemic administration of Company's novel delivery systems.

Molecular Profiles announces the continued expansion of its manufacturing capabilities with the recent purchase of the Xcelodose 120S system. The purchase of this system reflects the company's broader mission to expand the breadth and flexibility of its service offerings.